The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody....
Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively. Upadacitinib was effective in treating patients with moderate to severe atopic dermatitis (AD) after more than 1 year of continuous treat...
Drug points: Fever associated with cyclosporin for treating atopic dermatitis Cyclosporin is a fungal metabolite widely used in preventing graft rejection after tissue transplantation and in treating severe atopic dermatitis and psor... MD Thomas,LJ Cook - Bmj 被引量: 28发表: 1998年 Latest approache...
A novel hydrocortisone-ethanol gel ointment for treating atopic dermatitis (eczema) in children: A double blind, randomized, controlled clinical trial Importance: Current treatments for moderate to severe atopic dermatitis (AD) in children are limited by incomplete efficacy, long time to benefit, and...
Steroids will always have a role in atopic dermatitis. I don’t think any of these replace one another. We need a lot of good options to get these diseases under control. The other thing is, when we see patients with skin of color, when you put a steroid on the skin, you certainly...
20 patients suffering from severe atopic dermatitis were tested by using the mixture composition of Bamboo extract and Scutellaria extract selected from Experiment 1 for 4 weeks. The present composition was spread onto the popliteal fossa and the antecubital fossa, and the results were investigated....
2. Dupilumab: human monoclonal antibody against IL-4Rα for moderate to severe atopic dermatitis. [J] . D M Paton Drugs of today: Medicamentos de actualidad . 2017,第9期 机译:Dupilumab:针对IL-4Rα的人单克隆抗体,中度至重度特应性皮炎。 3. Dupilumab, A Monoclonal Antibody for Atopic De...
Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis Dupilumab, a novel anti-IL-4 receptor alpha monoclonal antibody, the first biologic agent approved for atopic dermatitis, was the drug of choice in this case. We observed remission of atopic dermatitis and a ...
[Use of traditional methods in medicine for treating moderately severe bronchial asthma]Minor therapeutic "cups" bloodletting, a variety of little known in Russia but conventional in China method, was compared in efficiency to chemotherapy,... VA Tarnuev,SA Radzievskiĭ,VG Kukes,... - 《Vopro...
In addition, investigators examining mpox therapeutics might focus their efforts on this population because they seem to possess the greatest risk of severe disease.39 Pharmacotherapy There is no specific Food and Drug Administration (FDA)–approved treatment for mpox; however, some antiviral and ...